PFE - These Biotechs Were Focused on One Line on Pfizer's Earnings Report
The $79 million that Vyndaqel contributed to Pfizer's (NYSE: PFE) third-quarter revenue doesn't mean a whole lot to the pharmaceutical giant. It amounted to a whopping 0.6% of the company's overall revenue.
But you can bet that executives at Alnylam Pharmaceuticals (NASDAQ: ALNY), Akcea Therapeutics (NASDAQ: AKCA), Ionis Pharmaceuticals (NASDAQ: IONS), and Eidos Therapeutics (NASDAQ: EIDX) were checking sales of the drug after its first full quarter on the market in the U.S.
Vyndaqel has been approved in Europe for a few years, but hadn't gotten much uptake based on lackluster data, which was so weak the Food and Drug Administration held off on approving the drug.